Press Release 2019 - Sami-Sabinsa Group | Formerly Known as Sami Labs Limited

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.

Sabinsa’s Four Indian Manufacturing Sites Achieve FSSC 22000 Certification

New Research Expands upon Use of Sabinsa’s Curcumin C3 Complex® as an Adjunct to Chemotherapy

Sabinsa’s Curcumin C3 Reduct® Self-Affirmed GRAS

Sabinsa Achieves USP GMP Audited Status for Three Additional Sites

Published Analysis of Curcumin Research Provides Comprehensive Overview

Sabinsa’s Manufacturing Arm Receives Research Funding From The Government of India

Certificates

Global Offices

Get in Touch

Disclaimer